Blastomycosis is a chronic fu ngal disease that pr imarily affects the lower respiratory tract. The acute inflammatory phase ofthe p rimary pulmo nary infection is characterized by a lymphohematogenous spread to extrapulmonary sites , especia lly the skin. Thepr esence ofdisseminated infect ion with Blastomyces dermatitidis in the larynx is unusual. In areas of the United States where this f ungus is endemic, fa ilure to consider laryngeal involvement might lead to inappropriate therapy and thus worsening inflammation and airway comp romise.
Introduction
Blastomyces dermatitidis is a dimorphou s soil-dwelling fungus that is found in the southeastern and centr al regions of the United States. Following the inhalation of aerosolized spore s into the lungs, the fungus changes into a yeast form, and it can give rise to a spectrum of clinical syndromes ranging from an acute, self-limited, flu-like illness to rapidl y progressive, widely dissemin ated, fatal disease. In northe ast Tennessee, 72 patients were diagnosed with blastomycosis from 1980 through 1995; the incidence quadrupl ed from 1988 through 1995. 1 In our experience with these patients, pulmonary involveme nt has been the most common feature (84.7% of patients), followed by cutaneous expressio n (32%).1
In this article, we report the case of a patient with laryngeal blastomycosis who came to us with complaints of respiratory distress and stridor that required emergency tracheosto my. Vocal fold involvement is unusual in blastomycosis. Nevertheless, it must be considered in the differential diagnosis of upper airway obstruction by clinicians who practice in geographic areas where blastomycos is is endemic.
Case report
A 55-year-old woman came to the emergency department with respiratory distress and fever. Her problem had begun 4 months earlier, when she developed hoarseness. Her evaluation at that time included an ENT examination, which revealed that her left vocal fold movement was impaired. Findings on computed tomography (CT) of her thorax were unremarkable, but a gallium scan was interpreted as showing bilateral enhancement of the lung parenchyma and the lacrimal glands. This pattern suggested sarcoidosis, and a diagnostic flexible bronchoscopy was performed . No endobro nchial lesion was observed. Bronch ial washings were negative for tuberculosis, fungal infection, and bacterial infection. Lung biopsy detected nonspecific inflammation. Based on the earlier interpretation of the gallium lung scan, the vocal fold impairme nt was believed to be consiste nt with laryngeal sarcoidosis. The patient was started on a daily dose of prednisone. Two months after the patient started prednisone therapy, her hoarseness worsened and she developed dyspnea and a nonproductive cough. Despite compliance with a maintenance glucocorticos teroid, her dyspnea progressively worsened until she came to the emerge ncy departm ent in respiratory distres s with inspiratory stridor.
In addition to her hoarseness and suspected sarcoidosis, the patient 's medical history was notable for a diagnosis of systemic lupus erythematosus and chronic thromb ocytopenia. She was known to have had a significantly positive purified protein derivative test, and she had completed 12 months of isoniazid prophylaxis 3 years earlier. She had never smoked tobacco and had no thyroid disease or history of malignancy. Approxi mately 12 months after she had finished her course of isoniazid prophylaxis, she devel oped a right upper lobe cavitary lesion, which was evident on chest x-ray and CT. Acidfast bacilli smears and cultures from sputum, bronchi al brushings, and washings were all negative. The samples tested for fungal infection and malignancy were also negative. She was treated empirically for active tuberculosis because of cough, a docum ented 40-lb weight loss, and night sweats. She completed standard therapy with 2 months of four-drug antituberculosis therapy (rifampin, isoniazid, ethambutol, and pyrazinamide) followed by 4 months of two-dru g therapy (rifampin and isoniazid).
Findings on the physical examination were remarkable for wheezing and high-pitched inspiratory breath sounds over the trachea. She had chronic nonpitting edema of both lower extremities. There was no lymphadenopathy, hepatosplenomegaly, or skin lesions. Indirect laryngoscopy detected exophytic lesions on the larynx and impendin g upper airway obstruction. The supraglottic area was diffusely inflamed (figure 1). An emergency tracheostomy was performed to guarantee a patent airway. Biopsy specimens of the laryngeal lesions contained multiple broad-based budd ing yeast cells that were consistent with blastomycosis (figure 2). There was an absence of caseating granuloma in the biopsy sample . Nonspecific tissue inflamm ation was again noted. Laboratory tests showed that the patient' s hemoglobin level was 11.3 g/dl, her leukocyte count was 9,800/mm 3 , and her differenti al count, electro1yte level, and urinalysis findings were within normal limits.
Prednisone was discontinued, and the patient was started on amphotericin B. Four weeks later, a repeat laryngoscopy showed that her laryngeal lesions had completely resolved. The tracheostomy tube was successfully removed, the amphotericin B was discontinued, and itraconazole at 400 mg/day was started.
At the 12-month follow-up, the patient had continued to improve. Her chest x-ray was normal, she was afebrile, and she had gained 10 lbs.
Discussion
Laryngeal blastomycosis is uncomm on. Accurate estimates of its prevalence are difficult to obtain becau se blastomycosis is not reported to the Centers for Disease Control and Prevention. Some insight into the prevalence of laryngeal blastomycosis has been provided by published reports of two large series. Of 102 patients with blastomycosis who had been treated at the Mayo Clinic, laryngeal involvement was seen in five (4.9%).2 A 10year collection of data in Mississippi revea led that laryngeal infection had been present in two of 326 blastomycosis patients (0.6%). 3 In their recent review of the Englishlanguage medical literature, Hanson et al"found that only 18 patients had been reported to have had primary or isolated laryngeal blastomycosis since Dennis' described the first case in 1918. Hanson et al added that many of these patients had received an initial incorrect clinical diagnosis of laryngeal carcinoma.'
Our patient was mistakenly thought to have had sarcoidosis based on the gallium-scan pattern, which showed an increase in lung and lacrimal uptake, and the fact that previous lung samples had been negative on fungal staining and culture. Becau se sarcoidosis can manifest as vocal fold paralysis.?" our patient was treated with an oral glucocorticosteroid. The T-Iymphocyte suppression brought about by the steroid likely favored the growth of laryngeal B dermatitidis and resulted in the impending upper air way obstruction.
Retrospectively, one can appreci ate that our patient had a typical presentation of laryngeal blastomycosis. The most common symp tom of lary ngeal invo lvement is persistent hoarseness over a perio d of several mon ths. Often, patien ts will also have sore throa t and dysphagia. " Systemic symptoms such as fever, nig ht sweats, malaise, and fatigue have also been described ."
Blastomycosis is believed to be a primary pulm onary infection that is caused by the inha lation of spore s that change into the yeast form in the warm environment of the lung . An inte nse inflammatory reaction follows, during which time the organism can reach extrapulmonary sites by Iymphohematogenous spread.10 The initial pulmonary infection might go unnoticed by the patient; subclinical pulmonary infections are frequently self-limited and resolve without specific intervention.I I When a patient does seek medical attention, the chest x-ray might show a variety of pulmonary parenchymal lesions, including local con solidation (28% of patients), mass-like lesions (23%), diffuse alveolar infi ltrates (13 %), and cavitary lung lesions (10 %).1 Involvement of the lary nx can occur as a result of the sprea d of quiescent pulmonary disease via a hematogenous route or as a res ult of fungus-laden sputum traversing the larynx and causing infection by direct inocul ation." Our patient had a right upper lobe cavitary lung lesion that, in the absence of a positive smear or culture, was treated as a tuberc ulosis reactivation. It is possible that her cavitary lesion, weight loss, and night sweats were expressions of pulmonary blastomycosis.
In such patients, examination of the larynx usually reveals erythematous and granular exophytic changes in the mucosa, whic h can involve any site between the epiglottis and subglottis.' Min ute grayi sh pap ules or larger yellow nodules, which repre sent small abscesses, might be seen superficially.s" Vocal fold movement might be imp aired by the surrounding inflammatory processes, a condition that mimics vocal fold paralysis.'
Findings on standard laboratory tests are nonspecific. The intradermal skin test for blastomycosis has proved to be useless because of its low degree of specificity and sensitivity." Serologic tests are available, but poor specificity also lim its their utility, partic ularly in areas of the country where other deep mycoses are endemic."
A definitive diagnosis can be made by the identification of the yeast form of B dermatitidis gro wn in colonies on Sabouraud's dextrose agar at 37°C after a 1-to 4-week 85 4 delay ." Unfortunately, it is difficult to cult ure the organism from diseased tissue. A presumptive diagnosis rests on the identification of the yeast form in the submitted tissue.' The spherical, thick -walled, bro ad-based yeast cell s (diameter: 10 to 20 urn ) can be identified in frozen sections or by any of the funga l-wall stains (potassium hydroxide, Gomori, and PAS) and on Papanicolaou stain ." Making the diagnosis without identification of the yea st form is hazardous because the histologic findi ngs can be misleadi ng. Essentially, there is a nonspecific inflammatory infiltra te associated with surface epithelial changes that can be confused with squamo us cell carcinoma.'
Oral itraconazole at 200 to 400 mg/day for 6 month s is the drug of choice for treatment of pulmo nary, cutaneous, or extrap ulmo nary blastomycosis that is not life-th reatening.16As an alterna tive , ora l fluco nazole at 400 to 800 mg/ day for at least 6 mo nths is effective in mo re than 85% of patients.I? In pa tients who do have life-threatening infection s, the drug of choice is amphotericin B at 0.5 mg/kg / day to a tota l of 1.5 g. 18 By 1998,72 cases of blastomycosis had been iden tified in northeast Tennessee .I The prev alence of the disease in this area is high. At the time of this writi ng, an additional 36 local cases have been identified, including a few cases of acute respiratory failure similar to acute respiratory distress syndrome.' ? We have determined that the incidence of lary ngeal blastomycosis in nort heast Tennessee is 1.1 % ( 1190), a fig ure that is consistent with those reported in other large series.P
In geographic areas where blastomycosis is ende mic , physicians should be aware that in additio n to the more commo n pulmonary and cutaneo us ma nifes tatio ns, laryngeal involvem ent is also possible, and it should be considered in patient s who have persistent hoarsene ss. Oth er diagnoses in patient s with laryngeal involvement (e.g., cancer, tubercul osis, and sarcoidosis) mig ht be more likely, but a fail ure to consider blastomycosis could lead to a critical or fatal outcome as a res ult of acute airway obstruction.
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